Anavex Life Sciences Corp.AVXLNASDAQ
LOADING
|||
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | -810.36% | +0.00% | +0.00% | +9.33% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +4.53% | +5.28% | +3.32% | +3.16% | +1.00% |
| Weighted Average Shares Diluted Growth | +4.53% | +5.28% | +3.32% | +3.16% | +1.00% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -20.56% | -9.60% | -27.95% | -82.40% | -52.33% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -10.31% | -12.19% | -16.23% | -19.07% | -27.63% |
| Book Value per Share Growth | -15.39% | -19.47% | -20.82% | -28.47% | -30.61% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +15.43% | +14.85% | +20.29% | +1.68% | -16.10% |
| SG&A Expenses Growth | -11.98% | +7.29% | +20.58% | -6.06% | +57.40% |